SLDB
Solid Biosciences Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 2 to Feb 4 ▼ 2 days of insider sells: $2.3M by 7 insiders, avg $6.44
- Mar 6 Solid Biosciences (SLDB) announced a $240 million private placement…
- Mar 11 ▲ Solid Biosciences reported updated positive interim data from its Ph…
- Mar 12 ▲ Solid Biosciences announced positive interim data from its Phase 1/2…
- Mar 19 ▲ Solid Biosciences reported financial results for Q4 and full year 20…
- Apr 1 ▼ Solid Biosciences Inc. has two S-3 shelf registration statements tha…
- May 7 FDA: Solid Biosciences Doses First Participant in Phase 3 IMPAC…
- May 7 ▲ Solid Biosciences dosed the first participant in its Phase 3 IMPACT…
- May 12 ▼ Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versu…
- Sep 30 ▲ Short interest falls 25.6% to 12.73M
- Oct 15 UBS initiates
- Oct 19 ▼ 1 insider sell $24.6K at $5.62
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $2.3M.
- InstitutionsBULLISH
Q3 2026: 18 added (0 new), 11 trimmed or exited.
- AnalystsBULLISH
18 of 19 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +8.2% to 13.30M shares. 10.7 days to cover, ≈11.9% of shares.
- TrendRANGE
9% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | DOUBLED | $8.5M |
| MORGAN STANLEY | DOUBLED | $8.3M |
| Qube Research & Technologies Ltd | DOUBLED | $7.4M |
| Invesco Ltd. | DOUBLED | $2.3M |
| RHUMBLINE ADVISERS | ADD | $1.2M |
| ALPS ADVISORS INC | ADD | $1.0M |
| AMERICAN CENTURY COMPANIES INC | ADD | $827.9K |
| Russell Investments Group, Ltd. | ADD | $462.2K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is below the lowest target. Median implies +185%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 15, 2026 | UBS INITIATE | Buy |
| Sep 16, 2026 | RBC Capital INITIATE | Outperform |
| Sep 14, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 27, 2026 | Cantor Fitzgerald MAINTAIN | Overweight |
| Aug 21, 2026 | Truist Securities MAINTAIN | Buy |
| Jun 3, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Brooks Gabriel Chief Medical Officer Oct 19, 2026 | SELL | $24.6K |
Brooks Gabriel Chief Medical Officer Oct 18, 2026 | EXERCISE | 9,750 sh |
SMITH IAN F Director Oct 2, 2026 | EXERCISE | 3,440 sh |
Ganot Ilan Director Oct 1, 2026 | AWARD | 150,000 sh |
SMITH IAN F Director Jul 2, 2026 | EXERCISE | 3,440 sh |
Stone Adam Leo Director Jun 10, 2026 | AWARD | 77,500 sh |
Ganot Ilan Director Jun 10, 2026 | AWARD | 77,500 sh |
Keresty Georgia Director Jun 10, 2026 | AWARD | 77,500 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.41 | -$0.53–-$0.35 | +6.6% | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 5 press releases · 1 bullish · 2 bearish · 6 neutral- NEUTRAL SC 13GNov 16, 2026
RTW Investments, LP disclosed a 5.5% passive stake in Solid Biosciences Inc., holding 5,905,426 shares as of September 30, 2026. This is a new 13G filing by RTW, indicating a meaningful but passive position in the biotech company.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13D/ANov 6, 2026
RA Capital Management filed Amendment No. 14 to its Schedule 13D for Solid Biosciences, reporting…
RA Capital's stake was diluted by the company's share issuance, not by selling. The pre-funded warrant blocker at 9.99% means RA Capital cannot increase its voting stake above that threshold without…
- NEUTRAL PRESS-RELEASENov 4, 2026
Solid Biosciences reported Q3 2026 net loss of $53.9M ($0.36 per share), wider than the $45.8M…
Watch for FDA Type C meeting outcome in late Q4 2026 regarding SGT-003 accelerated approval pathway, and initial SGT-212 data expected Q1 2027. Cash runway into H1 2028 provides buffer but ATM usage…
- NEUTRAL S-3ASRAug 6, 2026
Solid Biosciences filed an S-3ASR shelf registration statement, registering an unlimited amount of…
Monitor for any subsequent prospectus supplement that would indicate an actual debt offering. The shelf registration itself is routine and does not trigger a trading event. The company's cash…
All SLDB filing & press-release reports (14)
- SC 13G reportNov 16, 2026
- SC 13D/A reportNov 6, 2026
- PRESS-RELEASE reportNov 4, 2026
- S-3ASR reportAug 6, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportMay 7, 2026
- DEFA14A reportApr 23, 2026
- 8-K reportApr 10, 2026
- EFFECT reportApr 1, 2026
- PRESS-RELEASE reportMar 19, 2026
- 8-K reportMar 12, 2026
- PRESS-RELEASE reportMar 11, 2026
- PRESS-RELEASE reportMar 6, 2026
- PRESS-RELEASE reportMar 2, 2026